Iron chelation inhibits mTORC1 signaling involving activation of AMPK and REDD1/Bnip3 pathways
2020 · Oncogene · 37 citations
https://doi.org/10.1038/s41388-020-1366-5
H
Hongyu Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
84
Papers
3.4K
Citations
29
h-index
47
i10-index
Hongyu Zhou is an academic researcher from Kunming Institute of Botany. The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Protein Kinase Regulation and GTPase Signaling & Hematopoietic Stem Cell Transplantation. The author has an h-index of 29, co-authored 72 publications.
ORCID: 0000-0001-5852-3953Papers by this author
worksB591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
2019 · Oncogene · 36 citations
https://doi.org/10.1038/s41388-018-0674-5
Two mixed-NH3/amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group
2013 · Scientific Reports · 29 citations
https://doi.org/10.1038/srep02464
Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells
2023 · Natural Products and Bioprospecting · 18 citations
https://doi.org/10.1007/s13659-023-00392-1
Regulation of semaphorin 4D expression and cell proliferation of ovarian cancer by ERalpha and ERbeta
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.7899815
A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer
2025 · ESMO Open · 0 citations
https://doi.org/10.1016/j.esmoop.2025.105121
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat